Panitumumab: In metastatic colorectal cancer with wild-type KRAS

BioDrugs

Volumn 22, Issue 6, 2008, Pages 403-411

  Weber, Juliane ^a,b   McCormack, Paul L ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

Adis drug profiles; Colorectal cancer; Panitumumab, general; Research and development

Indexed keywords

PANITUMUMAB;

ABDOMINAL PAIN; ACNE; ANOREXIA; COLORECTAL CANCER; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; ERYTHEMA; FATIGUE; HUMAN; HYPOMAGNESEMIA; NAUSEA; ONCOGENE K RAS; PARONYCHIA; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; SKIN EXFOLIATION; SKIN FISSURE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; HUMANS; NEOPLASM METASTASIS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TREATMENT OUTCOME;

EID: 56049087993     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/0063030-200822060-00006     Document Type: Review

References (31)

1. WHO. Cancer [online]. Available from URL: http://www.who.int/mediacentre/ factsheets/fs297/en/index.html [Accessed 2008 Aug 27]
2. Board RE, Valle JW. Metastatic colorectal cancer: current systemic treatment options. Drugs 2007; 67 (13): 1851-67
3. Hoy SM, Wagstaff AJ. Panitumumab: in the treatment of metastatic colorectal cancer. Drugs 2006; 66 (15): 2005-14
4. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008 Apr 1; 26 (10): 1626-34
5. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007 Mar 15; 67 (6): 2643-8
6. European Medicines Agency. Vectibix® (panitumumab): summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/ humandocs/Humans/EPAR/vectibix/vectibix.htm [Accessed 2008 Sep 8]
7. Foltz IN, King CT, Liang M, et al. Panitumumab induces internalization of the epidermal growth factor receptor [abstract no. B43 plus poster]. 17th American Association for Cancer Research-National Cancer Institute-European Organisation for the Research and Treatment of Cancer (AACR-NCI EORTC) International Conference on Molecular Targets and Cancer Therapeutics; 2005 Nov 14-18; Philadelphia (PA), 136
8. Freeman D, McDorman K, Bush T, et al. Mono- and combination-therapeutic activity of panitumumab on human A431 epidermoid and HT-29 colon carcinoma xenografts: correlation with pharmacodynamic parameters [abstract no. 313]. EJC Supplements 2004; 2 (8): 95-6. Plus poster presented at the 16th European Organisation for the Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research (EORTC-NCI-AACR) Symposium on Molecular Targets and Cancer Therapeutics; 2004 Sep 28-Oct 1; Geneva
9. Starnes C, Freeman D, Bush T, et al. Antitumor activity of AMG 706, a novel tyrosine kinase inhibitor, in combination with panitumumab, a fully human antibody targeting the EGF receptor, against multiple established human tumor xenograft models in nude mice [abstract no. B73 plus poster]. 17th European Organisation for the Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research (EORTC-NCI-AACR) Conference on Molecular Targets and Cancer Therapeutics; 2005 Nov 14-18; Philadelphia (PA), 144
10. Polverino A, Coxon A, Starnes C, et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 2006 Sep 1; 66 (17): 8715-21
11. Rowinsky EK, Schwartz GH, Gollob JA, et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 2004 Aug 1; 22 (15): 3003-15
12. Weiner LM, Belldegrun A, Rowinsky E, et al. Updated results from a dose and schedule study of panitumumab (ABX-EGF) monotherapy, in patients with advanced solid malignancies [abstract no. 3059]. J Clin Oncol 2005 Jun 1; 23 (Suppl. 16 Pt I): 206s. Plus poster presented at the 41st American Society of Clinical Oncology (ASCO) Annual Meeting; 2005 May 13-17; Atlanta (GA)
13. Arends R, Yang BB, Schwab G, et al. Flexible dosing schedules of panitumumab (ABX-EGF) in cancer patients [abstract no. 3089]. J Clin Oncol 2005 Jun 1; 23 (Suppl. 16 Pt I): 214
14. Yang B-B, Hecht JR, Malik I, et al. Pharmacokinetics of panitumumab and irinotecan were not altered after first-line panitumumab therapy with irinotecan, 5-fluorouracil, and leucovorin in metastatic colorectal cancer patients [abstract no. 311P]. Ann Oncol 2004; 15 (Suppl. 3): iii83
15. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007 May 1; 25 (13): 1658-64
16. Hecht JR, Mitchell EP, Baranda J, et al. Panitumumab efficacy in patients with metastatic colorectal cancer with low or undetectable levels of epidermal growth factor receptor: final efficacy and KRAS analyses [abstract no. 343]. 2008 Gastrointestinal Cancers Symposium; 2008 Jan 25-27; Orlando (FL)
17. Yoshino T, Muro K, Doi T, et al. Phase 2 study of panitumumab (pmab) monotherapy in Japanese patients (pts) with metastatic colorectal cancer (mCRC) after the failure of fluoropyrimidine, irinotecan (CPT-11) and oxaliplatin (OHP) chemotherapy [abstract plus poster]. 2008 Gastrointestinal Cancers Symposium; 2008 Jan 25-27; Orlando (FL)
18. Van Cutsem E, Siena S, Humblet Y, et al. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol 2008 Jan; 19 (1): 92-8
19. Siena S, Peeters M, Van Cutsem E, et al. Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. Br J Cancer 2007 Dec 3; 97 (11): 1469-74
20. Data on file. Amgen Europe B.V., 2008
21. Amado RG, Wolf M, Freeman D, et al. Panitumumab (pmab) efficacy and patient-reported outcomes (PRO) in metastatic colorectal cancer (mCRC) patients with wild-type (WT) KRAS tumor status [abstract no. 278 plus poster]. 2008 Gastrointestinal Cancers Symposium; 2008 Jan 25-27; Orlando (FL)
22. Amado RG, Wolf M, Freeman D, et al. Association of KRAS mutational status and efficacy of panitumumab monotherapy for the treatment of metastatic colorectal cancer: results of pooled data from 4 clinical studies [abstract no. 359P]. Ann Oncol 2008 Sep; 19 Suppl. 8: viii126. Plus poster presented at the 33rd Congress of the European Society for Medical Oncology; 2008 Sep 12-16; Stockholm
23. Hecht JR, Patnaik A, Berlin J, et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 2007 Sep 1; 110 (5): 980-8
24. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005 May; 6 (5): 279-86
25. Sartore-Bianchi A, Moroni M, Veronese S, et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007 Aug 1; 25 (22): 3238-45
26. Berlin J, Hecht JR, Reiner M, et al. Association of gene copy number of the epidermal growth factor receptor and clinical outcome in patients with metastatic colorectal cancer treated with panitumumab monotherapy [abstract no. 3019]. EJC Supplements 2007 Sep 1; 5 (4): 241
27. Carcereny E, Castellvi-Bel S, Alonso V, et al. EGFR polymorphisms as predictors of clinical outcome in patients with advanced colorectal cancer (ACRC) treated with cetuximab and panitumumab [abstract no. 4124]. J Clin Oncol 2008 May 20; 26 Suppl.: 4124
28. National Cancer Institute. Cancer Therapy Evaluation Program: common terminology criteria for adverse events v3.0 (CTCAE) [online]. Available from URL: http://ctep.cancer.gov/forms/CTCAEv3.pdf [Accessed 2008 Sep 15]
29. ClinicalTrials.gov. Comparison of treatment effect of chemotherapy with panitumumab to chemotherapy alone [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00339183?term=panitumumab&id= 20050181&rank=1 [Accessed 2008 Nov 3]
30. ClinicalTrials.gov. PRIME: Panitumumab randomized trial in combination with chemotherapy for metastatic colorectal cancer to determine efficacy [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00364013? term=panitumumab&id=20050203&rank=1 [Accessed 2008 Nov 3]
31. US Food and Drug Administration. Vectibix® (panitumumab): US prescribing information [online]. Available from URL: http://www.fda.gov/cder/ foi/label/2008/125147s026lbl.pdf [Accessed 2008 Aug 27]